Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BBI-355 + BBI-825 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BBI-355 | BBI355|BBI 355 | CHK1 Inhibitor 18 | BBI-355 is a selective inhibitor of CHK1, which potentially induces cytotoxicity in tumor cells and antitumor activity (Cancer Res (2024) 84 (6_Supplement): 3631, Ann Oncol (2023) 34 (Suppl_2): S477). | |
| BBI-825 | BBI 825|BBI825 | BBI-825 inhibits ribonucleotide reductase, potentially leading to decreased tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): B082). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05827614 | Phase I | BBI-355 + BBI-825 BBI-355 + Futibatinib BBI-355 + Erlotinib BBI-355 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy, in Subjects With Tumors With Oncogene Amplifications (POTENTIATE) | Recruiting | USA | 0 |